OptimizeRx Q3 2025 Earnings Report

OptimizeRx EPS Results

• Actual EPS: $0.20
• Consensus EPS: $0.03
• Beat/Miss: Beat by +$0.17
• One Year Ago EPS: N/A

OptimizeRx Revenue Results

• Actual Revenue: $26.07 million
• Expected Revenue: $23.83 million
• Beat/Miss: Beat by +$2.23 million
• YoY Revenue Growth: N/A

OptimizeRx Announcement Details

• Quarter: Q3 2025
• Date: 11/6/2025
• Time: After Market Closes
• Conference Call Date: Thursday, November 6, 2025
• Conference Call Time: 4:30PM ET

OptimizeRx (NASDAQ:OPRX), Inc. is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations. These tools allow pharmaceutical and biotechnology firms to deliver personalized messaging to physicians and care teams, ensuring that relevant formulary and financial support information is accessible at the moment of treatment. In addition, OptimizeRx provides data analytics and reporting capabilities that enable clients to measure the impact of their digital outreach and refine strategies to drive prescription growth and patient outcomes.

Founded in 2003 and headquartered in Cleveland, Ohio, OptimizeRx has formed partnerships with a broad spectrum of EHR vendors and health systems across the United States. The company’s network reaches tens of thousands of healthcare providers, making it one of the largest point-of-care communication platforms in the country. OptimizeRx collaborates closely with payers to integrate eligibility and benefit information, ensuring that savings offers and coverage details are accurate and up to date.

OptimizeRx is led by Chief Executive Officer David Whitlinger, who joined the company in 2019 and has overseen its expansion of digital service offerings and strategic alliances. Under his leadership, the company has focused on enhancing interoperability, scaling its network footprint and delivering advanced analytics to clients. While its primary market remains the U.S., OptimizeRx continues to explore opportunities to extend its digital health network into new regions and therapeutic areas.

OptimizeRx Q3 2025 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: Shift to a predictive, contracted‑revenue model — management is giving more visibility (including into 2026) and stressing conservative guidance built on contracted revenue rather than pipeline.
• Positive Sentiment: RFPs and win rates are improving — RFP season is strong with increased digital demand across HCP and DTC, plus growing traction among mid‑tier pharma customers who can now access capabilities they previously couldn't afford.
• Negative Sentiment: Q4 guidance is cautious — the top end of fourth‑quarter revenue guidance is roughly flat-to-down year‑over‑year because management is excluding pipeline “bluebirds” and focusing only on bookings with clear visibility.
• Positive Sentiment: Margins and profitability outlook improving — Q3 gross‑margin expansion was driven by product and channel mix (growth in DAP/GTC and better channel economics); management expects gross margins in the upper‑50s to low‑60s range and modest adjusted‑EBITDA margin expansion into 2026.

Presentation

[Steve Silvestro, CEO at OptimizeRx]

And also to our clients and investors, that we're going to give more visibility on our visibility into the future as we've been migrating more toward a predictive model. We've quoted in the past subscription momentum, and so we're going to continue to push that throughout the remainder of the year, and as a result of that, we're now getting more visibility into the out years, including 2026. In terms of the RFP situation, Ryan, RFP season's been very strong for the business. We do see more people coming into the digital space and making investments on the client side. And we're seeing equal parts HCP and DTC at this point, interest in the RFP cycle. I would say the parts of DTC that we cover at OptimizeRx are CTV, ATV, the pieces that you're aware of.

[Steve Silvestro, CEO at OptimizeRx]

And in the event that we have a linear television ban or reduction or any of those pieces, our view and thesis is that our solution set will continue to benefit disproportionately from those types of moves. So I would say at this point, both DTC and HCP are looking very healthy. I appreciate the question.

Perfect. Thank you so much. I'll hop back in the queue.

[Steve Silvestro, CEO at OptimizeRx]

You got it. Thanks, man.

[Operator]

Thank you, and the next question comes from Richard Baldry with Roth Capital.

[Richard Baldry, Senior Analyst at Roth Capital]

Thanks. When you look at the implied guidance for fourth quarter revenue, it'd be actually slightly down year-over-year at the top end of guidance. Talk about either any one-time year-ago issues or other things, because your net retention would argue that that's sort of difficult to do.

[Steve Silvestro, CEO at OptimizeRx]

Yeah, thanks for the question, Rich. Good to hear from you. So I mean, what we're looking at is really a full-year guide at this point and trying to give a good range of what we believe we'll come in at. We moved away from quoting pipeline, as everybody on the call knows, and have moved principally toward contracted revenue and what our real visibility is. And so the new guidance that we've updated with is truly what our visibility is. It doesn't count bluebird that might happen, buyups that might happen that are not accounted for right now, or we don't have visibility. In years past, we would have thought about that more in terms of pipeline and probabilities. But what you're seeing in the guidance now is, I think, reflective of our true visibility that we know we can deliver on.

[Steve Silvestro, CEO at OptimizeRx]

Again, we're going to continue to be very transparent, very conservative, not sandbagging, but look to beat the numbers that we put out there every time. Hopefully you appreciate the transparency and conservatism.

[Ed Stelmakh, Chief Financial and Strategic Officer at OptimizeRx]

Yeah. And just to add to that, yeah, sorry. Just to add a little bit, as Steve said, I think we do need to look at it on a full-year basis rather than quarter by quarter. As you know, Q1, Q2, and Q3 have been extremely strong. So it is more of a smoother sort of phasing this year than it was in the past. So again, I would just encourage you to look at the full-year performance versus last year.

[Steve Silvestro, CEO at OptimizeRx]

And part of it is the enhancement to the revenue model, right, Rich? Part of it is we've been successful at migrating away from periodic revenue drops and getting to a more smooth revenue model. And so that's what Ed is referring to there.

[Richard Baldry, Senior Analyst at Roth Capital]

Got it. It's just implicitly a little hard to look at it as a full year. We only have 90 days left. So the same question, I think I'm going to get a similar answer. But if you look at the Adjusted EBITDA guidance, you'd have an up revenue quarter, maybe 10% plus sequentially, but the Adjusted EBITDA would either be slightly down to narrowly, possibly up. Again, is there any one-time expenses, year-end, things that true up higher that create more of a headwind because it wouldn't still be down year-over-year as well? Thanks.

[Steve Silvestro, CEO at OptimizeRx]

Sure. Ed, do you want to take that one?

[Ed Stelmakh, Chief Financial and Strategic Officer at OptimizeRx]

Yeah, I can take that one. Yeah. Yeah, look, I mean, we're assuming a conservative gross margin number. There's nothing really in the operating expense line that's going to pop. So it's more of just being a little bit more conservative on what we think is going to happen with the channel and product mix. We do believe that we're shooting for hitting or beating the top end of the range.

[Richard Baldry, Senior Analyst at Roth Capital]

Got it. Thanks.

[Steve Silvestro, CEO at OptimizeRx]

Thanks, Rich. Appreciate the support.

[Operator]

Thank you. And the next question comes from David Grossman with Stifel Financial.

[David Grossman, Research Managing Director at Stifel Financial]

Great. Thanks.

[David Grossman, Research Managing Director at Stifel Financial]

Hey, guys. Maybe we could just expand a little bit on the line of questioning you just went through. And maybe, Steve, take a minute just to remind us of fundamentally what may be going on in the business that may be smoothing out the quarters or maybe giving you better visibility. And then I have another question after that, but just curious again, fundamentally, some of the changes that you guys have made that may be creating a little better visibility and, again, giving you the confidence, for example, to guide to 2026 at this point.

[Steve Silvestro, CEO at OptimizeRx]

Sure. Yeah, happy to talk to it. And then Andy and Ed can chime in also.

[Steve Silvestro, CEO at OptimizeRx]

But I mean, if you think about our business data the way that we've talked about it over time, you've got our audience businesses, which is DAAP principally, and then you've got Micro-Neighborhood audience, which is that targeting capability for DTC. Both of those are data-driven technologies that lend themselves to becoming more subscription in nature. Then you've got our execution functions, both at point of care and the other omnichannel components for HCP, and you've got that for DTC. And those are obviously going to be transactional largely because that's the way that component of not just our business, but the ecosystem operates. And so what we've seen is outsized growth in DAAP, like we've talked about in months past, and we've seen a resurgence of Micro-Neighborhood audience growth.

[Steve Silvestro, CEO at OptimizeRx]

And so those pieces not only give us a smoothing of the revenue because of the revenue models, but they also give us a renewable view into what 2026 will look like. And those contracts start earlier than we would normally do for transaction-level contract, right? So that's the big part of it. Andy, Ed, feel free to chime in if you want to add more.

[Andy D'Silva, Chief Business Officer at OptimizeRx]

Yeah, I mean, it's really. Go ahead, Ed.

[Ed Stelmakh, Chief Financial and Strategic Officer at OptimizeRx]

No, I was going to say, I mean, as you guys know, I mean, the vast majority of our business comes from renewals. So if you take that into account and then add some of the successes that drove this year on top of it, with more visibility into next year in terms of signed contracts, as we sit here today, we feel like we're in a position to say, "All right, looking at next year, we can start to make at least a general guide around bookends that we're going to shoot for." And as things progress forward, we'll continue to tighten that range. Yeah, go ahead, Andy. You can add to that.

[Andy D'Silva, Chief Business Officer at OptimizeRx]

No, you got it. You both nailed it.

[Ed Stelmakh, Chief Financial and Strategic Officer at OptimizeRx]

All right. Yeah.

[David Grossman, Research Managing Director at Stifel Financial]

Thanks for all those details. If I recall, last quarter, we talked about these managed services type of contracts that come in. How much of that was present in the third quarter? And are you kind of making the same assumption that you did last quarter, where you're not assuming any of that comes to bear in the fourth quarter in terms of the guidance that you provided, as well as the outlook for 2026? Is that the way to think about it?

[Steve Silvestro, CEO at OptimizeRx]

Yeah. Andy, why don't you take that one?

[Andy D'Silva, Chief Business Officer at OptimizeRx]

Yeah. So it went back to more of a normalized rate in the third quarter as it relates to that managed services business. The only thing that we're including in the forecast period for managed services business is stuff that we've already won and is starting to burn into revenue right now. We're not really including anything that's in pipeline if we don't have visibility to. So again, we're taking a very conservative approach to providing guidance with bookends that we feel very comfortable with.

[David Grossman, Research Managing Director at Stifel Financial]

Right. So as we kind of think of your guidance for 2026, can you help us kind of bracket the kind of retention that is the baseline, if you will, to achieve that range?

[Andy D'Silva, Chief Business Officer at OptimizeRx]

Yeah. So historically, between five and 15% of our business comes from new logos every year. So the remaining would be what you would consider net revenue retention on a normalized basis.

[David Grossman, Research Managing Director at Stifel Financial]

Okay. And that's the same assumption underlying your 2026 guidance?

[Steve Silvestro, CEO at OptimizeRx]

It is.

[Andy D'Silva, Chief Business Officer at OptimizeRx]

Yeah. Yeah. We don't really guide based on net revenue retention, right? But that's kind of how it just shakes out as every year progresses.

[David Grossman, Research Managing Director at Stifel Financial]

Got it.

[Steve Silvestro, CEO at OptimizeRx]

Great. And then on that note, David, on that note, just one other quick bullet for you. And you and I spoke about this last time we were together. We are seeing a good growth in the mid-tier segment of our business, meaning the mid-tier segment of clients coming to the table who may not be in that top 20, 25, 30 manufacturers that are coming in with outsized spend, mostly because we're able to provide capabilities that can supplement, not just supplement, frankly, replace a lot of the stuff that they can't afford to do internally, whereas the big manufacturers might have kind of Cadillac support, so to speak. The mid-tier businesses do not. But using the technology that we've got allows them to compete on level ground. And so that's why we're seeing such a drive there.

[Steve Silvestro, CEO at OptimizeRx]

Our commercial organization that Theresa's leading has done a wonderful job of driving that. Just wanted to call that out as a key point.

[David Grossman, Research Managing Director at Stifel Financial]

Got it. All very helpful. Thanks very much. Appreciate it.

[Steve Silvestro, CEO at OptimizeRx]

You got it. Great to hear your voice. We'll talk soon.

[David Grossman, Research Managing Director at Stifel Financial]

Yep.

[Operator]

Thank you. And the next question comes from Eric Martinuzzi with Lake Street.

[Eric Martinuzzi, Senior Research Analyst at Lake Street]

Yeah, I wanted to dive in on the RFP trends. You talked about them improved. I was just curious to know, is that your win rate is the same and the number of RFPs is improved, or is your win rate improving on a flat RFP trend? What can you tell us there?

[Steve Silvestro, CEO at OptimizeRx]

Yeah, I'll start, and then I'll have Andy chime in too. But all of the above, Eric, we're seeing more RFPs come in. The RFPs are more directly pointed at what we want them to be, which I think is good. The market is seeing what we're shifting the business model to over time. So the RFPs are definitely reflective of what we're providing the market, providing our clients. And I would say our win rate as a result of that is getting better. Again, I want to give some credit to our commercial team. They're doing an excellent job of getting out ahead of all of this stuff and engaging with clients.

[Steve Silvestro, CEO at OptimizeRx]

When you're engaging with clients more intimately, you can tend to drive the crafting of the RFPs so that they get written at an appropriate level to something that you can respond versus just a random spray and pray request for information, right? When we get those, the hit rate will be lower because there was no prior engagement. Hats off to Jim Dwyer, Theresa Greco, and the entire commercial team for doing a great job there.

[Eric Martinuzzi, Senior Research Analyst at Lake Street]

All right. And then you talked about the smoothing of the business. Maybe I could use a brief tutorial on the transactional, where you said that those started later in the year as opposed to the DAAP and the Micro-Neighborhood that are more sort of level loaded, the kickoffs to each of those types of campaigns.

[Steve Silvestro, CEO at OptimizeRx]

Sure. Yeah, happy to talk about it. I mean, you think about what DAAP and what MNT or M&A does, it's principally audience creation, and it's the data that drives all of the campaigns, right? It's the technology that's producing, finding those patients wherever they're going to be. And so because that is more of a software-like play, it lends itself to a normal planning cycle where renewals are going to happen earlier. That's just the way pharma manages that segment of their budget. And then the transactional components, which is typically message distribution, whether it's at an HCP level or if it's something that's going through a DSP, like The Trade Desk or some other way, typically is budgeted and accounted for on a quarterly basis. And it's based on performance and driven that way.

[Steve Silvestro, CEO at OptimizeRx]

So bringing DAAP to the table and getting it more mature, which we've been working very hard on, as you know, over the last several years since we launched it, and now bringing in what we acquired through the Medicx acquisition with MNT, that has really started to transform the profile of the business. And that's what you're seeing reflected in the performance of this year as well. You're seeing it front and center, but it will reflect into 2026 as well. That's given us great visibility. I think everyone feels better about what we're doing there. We're significantly up year-over-year on visibility for next year.

[Eric Martinuzzi, Senior Research Analyst at Lake Street]

What's the right way to think about the percentage of the revenue in 2025 versus the percentage of the revenue in 2026 between those two buckets?

[Steve Silvestro, CEO at OptimizeRx]

Yeah, we don't break it out. We don't break it out at a product level.

[Eric Martinuzzi, Senior Research Analyst at Lake Street]

Yeah. Okay. Thanks for taking my questions.

[Steve Silvestro, CEO at OptimizeRx]

You got it. Great questions. Thanks.

[Operator]

Thank you. And the next question comes from Anderson Schock, B. Riley Securities.

[Anderson Schock, MedTech Equity Research Analyst at B. Riley Securities]

Hi. Thank you for taking the questions, and congratulations on another really strong quarter. So first, could you provide some color on the partnership with Lamar Advertising and on the size of the opportunity here? And I guess, will this gradually roll out in specific regions, or is this going live across their entire national inventory?

[Steve Silvestro, CEO at OptimizeRx]

Yeah. Happy to talk about it. Great to hear from you. So the whole idea with Lamar is they're looking to transform their business model, right? And their current business model is billboards. And one of the things that OptimizeRx does really well, which you're acutely aware of, is patient finding and an ability to be more precise in the way that we deploy messages across our omnichannel ecosystem. So think about the capability of doing that to enable a screen that's in a desirable location that might move from a random billboard to maybe a digital screen that's large, right? And that's really what Lamar is after there. The size of the opportunity is very large. I'm not going to take a stab at the TAM because it's not mine to take a stab at. It's really theirs.

[Steve Silvestro, CEO at OptimizeRx]

But the partnership is going to start rolling out pretty rapidly, I would say. And it's still early for us to start quoting projections on what we think it'll do. It's really piloting at this point, but we're feeling pretty optimistic about the initial testing that we've done. And we'll release more information on it as we get some more results. But early stages look pretty encouraging.

[Anderson Schock, MedTech Equity Research Analyst at B. Riley Securities]

Okay. Got it, and then I guess, does current guidance that you've provided for 2026 factor in any contributions from this partnership?

[Steve Silvestro, CEO at OptimizeRx]

No. Zero. Nothing. Too early for us to start factoring it into forecasts. We're just not going to do it yet. Great question, though.

[Anderson Schock, MedTech Equity Research Analyst at B. Riley Securities]

Yep. And then could you talk about the gross margin expansion in the third quarter? What really drove this, and how should we be thinking about margins going forward in the fourth quarter and also into 2026?

[Steve Silvestro, CEO at OptimizeRx]

Sure. Ed, you want to take that one?

[Ed Stelmakh, Chief Financial and Strategic Officer at OptimizeRx]

Yeah, sure. Yeah. So look, I mean, it's typically driven by our product mix or solution mix and the channel partner mix. As we said before, as we scale the business, we have much more ability to negotiate more favorable deals with our channel partners. So that's reflecting itself in the numbers, as well as growth in DAAP and the DTC platform. So those two things together contributed to where we are right now for the year and the Q4. Going forward, I would say we're kind of stabilizing in that upper 50s to low 60s range from a guidance perspective. But you can see that it's certainly upside to that number as the year progresses.

[Anderson Schock, MedTech Equity Research Analyst at B. Riley Securities]

Okay. Got it.

[Andy D'Silva, Chief Business Officer at OptimizeRx]

I'll add just one quick thing to that there, Anderson, so we also, in the third quarter, had a lot more or in the second quarter, had a lot more managed services revenue, and we did not have nearly as much in the third quarter, and managed services revenue is our lowest margin product.

[Anderson Schock, MedTech Equity Research Analyst at B. Riley Securities]

Okay. Got it. Thank you for that. And congrats again on the great quarter.

[Steve Silvestro, CEO at OptimizeRx]

Thank you. Thanks. Great to hear from you.

[Operator]

Thank you. And once again, please press star, then one if you would like to ask a question. And the next question comes from Jeff Garro with Stephens.

[Jeff Garro, Managing Director and Equity Research Analyst at Stephens]

Yeah. Good afternoon. Thanks for taking the question. Want to ask on the 2026 guide and the profitability side. If I calculate it right, at the midpoint, I see about 60 basis points of EBITDA margin expansion. Was hoping you could talk about the mix of gross margin expansion, maybe dependent on channel mix versus operating leverage, and then any areas of potential variability that could lead to more or less margin expansion than what we see at the midpoint there? Thanks.

[Steve Silvestro, CEO at OptimizeRx]

Yeah. Jeff, I'm happy to answer it topically. And we won't get too deep into 2026, but happy to answer it topically. And what Andy just said is really a clear articulation of the dynamics of the business that really govern it, right? So as we continue to see our audiences grow over time through the DAAP and MNT products, margin expansion will continue to be front and center. We will also manage the channel partner mix on the other side of that, looking for optimal margin. And that gives us the dynamic of being able to continue to improve over time. Execution will be what it's going to be, as you know, from this business. And that's fairly predictable on the highs and lows. But those are the dynamics that are sort of shaping how we're thinking about 2026 gross margin expansion opportunities and where we've landed.

[Steve Silvestro, CEO at OptimizeRx]

I hope that's helpful.

[Jeff Garro, Managing Director and Equity Research Analyst at Stephens]

Yeah. Maybe a follow-up on the operating leverage side of things. We've certainly seen, I think, a quarter-over-quarter decline in adjusted operating expenses this quarter, seeing really good leverage. And maybe not expecting that to be the persistent trend over the next five or so quarters. But just a little more color commentary on your ability to drive additional operating leverage in the business would be helpful. Thanks.

[Steve Silvestro, CEO at OptimizeRx]

Yeah. Yeah. No problem.

[Steve Silvestro, CEO at OptimizeRx]

Yeah. I think we're going to consistently.

[Steve Silvestro, CEO at OptimizeRx]

Yeah. Go ahead, Ed. Yeah. Why don't you take it?

[Steve Silvestro, CEO at OptimizeRx]

Go ahead.

[Ed Stelmakh, Chief Financial and Strategic Officer at OptimizeRx]

Yeah. So OpEx, as we said before, I mean, we have a highly leverageable business model as it is now. So as I said, on a cash basis, there was actually a bit of an increase, about $2 million versus last year. And most of that is driven by the fact that our bonuses and variable comp are tracking our overperformance on the top line this year. So once you dial that back, you can pretty much assume a relatively stable operating expense run rate on a cash basis.

[Jeff Garro, Managing Director and Equity Research Analyst at Stephens]

Understood. Thanks for taking the questions, guys. Congrats again.

[Steve Silvestro, CEO at OptimizeRx]

Thank you.

[Operator]

Thank you. This concludes our question and answer session. I want to turn the conference back over to Steve Silvestro for any closing comments.

[Steve Silvestro, CEO at OptimizeRx]

Thank you, operator, and thank you all for joining us today. We're pleased to be building on strong operational and financial momentum. Our foundation is solid. Our patient-focused strategy is working, and we're confident in the path ahead. What you heard today reinforces our belief in our ability to achieve both our near-term goals and our long-term growth objectives. I remain deeply optimistic about the future of our business and the opportunities before us. We look forward to speaking with all of you again on the next earnings call and meeting many of you in the upcoming investor conferences and one-on-one meetings in the coming weeks. Wishing everyone a wonderful rest of your day and a wonderful holiday season with your families and friends.

[Operator]

Thank you, Mr. Silvestro. Before we conclude today's call, I would like to provide the company's safe harbor statement that includes important cautions regarding forward-looking statements made during today's call. Statements made by management during today's call may include forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements should not be used to make investment decisions. The words anticipate, estimate, expect, possible, and seeking, and similar expressions identify forward-looking statements. These may speak only to the date that such statements are made.

[Operator]

Forward-looking statements in this call include statements made defining how pharmaceutical companies, patients, and prescribers connect our growth paths, creating shareholder value, becoming a Rule of 40 company, estimated 2025 revenue, and Adjusted EBITDA ranges, capturing greater market share, expanding our participation in the pharma industry's digital ecosystem, our technology and growth opportunities, and building a strong operational and financial momentum. Forward-looking statements also include the management's expectations for the rest of the year. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or qualified. Future events and actual results could differ materially from those set forth and can complicate or undermine these forward-looking statements.

[Operator]

The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effects of government regulation, competition, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contacts with electronic prescription platforms and electronic health records networks, and the material risks discussed in the company's annual report on Form 10-K for the year ended December 31st, 2024, and other communications the company has made and may make with the SEC in the future. These filings, when made, are available on the company's website and on the SEC website at sec.gov.

[Operator]

Before we end today's conference, I would like to remind everyone that an audio recording of this conference call will be available for your replay starting later this evening, running through for a year on the Investor Relations section of the company's website. Thank you for joining us today. This concludes today's conference, and you may now disconnect your lines.

Participants

Executives

• Andy D'Silva, Chief Business Officer
• Ed Stelmakh, Chief Financial and Strategic Officer
• Steve Silvestro, CEO

Analysts

• Anderson Schock, MedTech Equity Research Analyst at B. Riley Securities
• David Grossman, Research Managing Director at Stifel Financial
• Eric Martinuzzi, Senior Research Analyst at Lake Street
• Jeff Garro, Managing Director and Equity Research Analyst at Stephens
• Richard Baldry, Senior Analyst at Roth Capital